Valuemetrix
    Influencer PortfoliosFeaturesCalculatorsPricingBlogs
    LoginGet Started
    HomeVoyagerAIPortfolio
    Valuemetrix
    Influencer PortfoliosFeaturesCalculatorsPricingBlogs
    LoginGet Started
    A

    Amryt Pharma plc

    AMYT

    $14.70 USD

    0.00 (0.00%)
    NASDAQ:AMYT
    • Overview
    • Main Ratios
    • Valuation
    • Future Growth
    • Past Performance
    • News
    • Financial Health
    • Earning Call Insights
    • Ownership
    • Financial
    • Filings
    Signup is free and no credit card is required.
    HomeAMYT:NASDAQ
    A

    Amryt Pharma plc

    $14.70USD

    0.00%0
    0.00
    IE
    NASDAQ
    Healthcare
    Drug Manufacturers - Specialty & Generic

    Year range

    14.70 - 14.71

    Market cap

    $0 USD

    Avg Volume

    2.38M

    P/E ratio TTM

    -38.16

    Dividend yield TTM

    0.00%

    Primary exchange

    NASDAQ Global Select

    Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan dise... Read more

    CEO

    Dr. Joseph A. Wiley

    Employees

    289

    Website

    amrytpharma.com

    Country

    IE

    IPO Date

    Jul 8, 2020

    Headquarters

    45 Mespil Road, Dublin

    Phone

    +353 1 518 0200

    Advanced Financial Analysis

    Powerful insights without barriers. No credit card or login required.

    Global Stocks, ETFs & Fund Coverage
    Unlimited Monthly Prompts
    Chat with Voyager: AI Chatbot
    Unlimited Monthly Company Reports
    5 Portfolios with Unlimited Holdings
    Watchlist Functionality
    30 Years of Financial Data
    Analyst Estimates & Ratings
    Priority Support
    Free access to financial analysis tools. No credit card required.
    NumbersChart Mode
    Valuemetrix
    Sign up
    Enter your information to create your account

    Already have an account?

    By contining, you agree to our Terms of Service and Privacy Policy.

    1Main Ratios

    Key financial ratios and metrics that provide insights into a company’s valuation, solvency, efficiency, and growth.

    valuation
    P/E:
    -38.16
    P/B:
    2.05
    P/S:
    0.00
    P/FCF:
    0.00
    EV/EBITDA:
    2.97
    EV/Sales:
    0.39
    PEG Ratio:
    -0.38
    Dividend Yield:
    0.00%
    DPS:
    $0.00
    solvency
    EV:
    $86.41M
    Debt to Equity:
    0.59
    Interest Coverage:
    -0.78
    Cashflow to Debt:
    0.08
    Debt Ratio:
    0.57
    Long Term Debt to Capitalization:
    0.37
    Current Ratio:
    1.80
    Cash Ratio:
    0.72
    efficiency
    Return on Equity:
    -9.00%
    Return on Capital Employed:
    -3.46%
    Operating Profit Margin:
    -9.72%
    Net Profit Margin:
    -8.17%
    Asset Turnover Ratio:
    0.28
    Inventory Turnover Ratio:
    0.92
    Receivables Turnover Ratio:
    4.13
    growth CAGR
    Revenue Growth (1Y):
    Net Income Growth (1Y):
    Revenue Growth Per Share (5Y):
    Net Income Growth Per Share (5Y):
    Operating Cashflow Growth (1Y):

    Was this helpful?

    2Valuation

    3Future Growth

    This section provides an overview of the future growth of the company.

    3.1

    Future Estimates

    4Past Earnings Performance

    5Recent News and Updates for AMYT

    7Earning Call Insights AMYT

    Period

    Held On

    Was this helpful?

    8

    Ownership

    Who are the major shareholders and have insiders been buying or selling?

    8.1

    Recent Insider Transactions

    NASDAQ:AMYT Recent Insider Transactions by Companies or Individuals

    Was this helpful?

    9Financials of AMYT

    10Filings of AMYT

    Was this helpful?

    • For Investors
    • Contact

    © Valuemetrix.io 2025.

    HomeVoyagerAIPortfolio

    6Financial Health for Amryt Pharma plc

    6.1

    Financial Strength Ratios

    Liquidity

    Leverage

    Financial Strength

    6.2

    Financial Strength Historical

    Was this helpful?

    6.3

    Financial Position Analysis

    Valuemetrix

    Short Term

    Valuemetrix

    Long Term
    6.4

    Debt to Equity History and Analysis

    Was this helpful?